We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





Blood Test Performed During Initial Infection Predicts Long COVID Risk

By LabMedica International staff writers
Posted on 30 Sep 2022
Print article
Image: The scanning electron microscope image shows SARS-CoV-2 (yellow) (Photo courtesy of NIAID-RML)
Image: The scanning electron microscope image shows SARS-CoV-2 (yellow) (Photo courtesy of NIAID-RML)

A blood test taken at the time of COVID-19 infection could predict who is most likely to develop long COVID, suggests a new small-scale study. The study analyzed proteins in the blood of healthcare workers infected with SARS-CoV-2, comparing them to samples from healthcare workers who had not been infected. Usually protein levels in the body are stable, but the researchers found a dramatic difference in levels of some of the proteins up to six weeks following infection, suggesting disruption to a number of important biological processes. Using an artificial intelligence (AI) algorithm, they identified a “signature” in the abundance of different proteins that successfully predicted whether or not the person would go on to report persistent symptoms a year after infection. The researchers say that, if these findings are repeated in a larger, independent group of patients, a test could potentially be offered alongside a polymerase chain reaction (PCR) test that could predict people’s likelihood of developing long COVID.

For the study, researchers at University College London (London, UK) analyzed blood plasma samples from 54 healthcare workers who had PCR- or antibody-confirmed infection, taken every week for six weeks in spring 2020, comparing them to samples taken over the same period from 102 healthcare workers who were not infected. They used targeted mass spectrometry, a form of analysis that is extremely sensitive to tiny changes in the amount of proteins in blood plasma, to look at how COVID-19 affected these proteins over the course of six weeks. The researchers found abnormally high levels of 12 proteins out of the 91 studied among those infected by SARS-CoV-2, and that the degree of abnormality tracked with the severity of symptoms.

The research team found that at the time of first infection, abnormal levels of 20 proteins studied were predictive of persistent symptoms after one year. Most of these proteins were linked to anti-coagulant (anti-clotting) and anti-inflammatory processes. A machine learning algorithm, trained on the protein profiles of the participants, was able to distinguish all of the 11 healthcare workers who reported at least one persistent symptom at one year, from infected healthcare workers who did not report persistent symptoms after a year. Another machine learning tool was used to estimate the likelihood of error and suggested a possible error rate of 6% for this method.

“Our study shows that even mild or asymptomatic COVID-19 disrupts the profile of proteins in our blood plasma. This means that even mild COVID-19 affects normal biological processes in a dramatic way, up to at least six weeks after infection,” said Dr. Gaby Captur, MRC Unit for Lifelong Health and Ageing at UCL and lead author. “Our tool predicting long COVID still needs to be validated in an independent, larger group of patients. However, using our approach, a test that predicts long COVID at the time of initial infection could be rolled out quickly and in a cost-effective way. The method of analysis we used is readily available in hospitals and is high-throughput, meaning it can analyze thousands of samples in an afternoon.”

Related Links:
University College London 

Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac
New
Immunofluorescence Analyzer
MPQuanti

Print article

Channels

Clinical Chemistry

view channel
Image: The research team has developed the uCR-Chip device to enhance kidney function testing (Photo courtesy of University of Manitoba)

Low-Cost Portable Screening Test to Transform Kidney Disease Detection

Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.